Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China

/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of...

Related Keywords

Canada ,China ,Beijing ,Shanghai ,United States ,Peking ,Lin Shen ,Guangdong ,America ,Zonghai Li ,Carsgen Therapeutics Holdings ,University Cancer Hospital ,Prnewswire Carsgen Therapeutics Holdings Limited Stock Code ,Department Of Gastrointestinal Oncology ,National Medical Products Administration ,Health Canada ,Institute For Cancer Research ,Therapeutics Holdings Limited ,Stock Code ,Drug Evaluation ,Vice President ,Peking University Cancer Hospital ,Gastrointestinal Oncology ,Phasei Clinical Study Ward ,Deputy Director ,Beijing Institute ,Cancer Research ,Chief Executive Officer ,Chief Scientific Officer ,Orphan Drug ,Orphan Medicinal Product ,Regenerative Medicine Advanced Therapy ,North America ,Therapeutics Holdings ,Carsgen Therapeutics ,